


Decernotinib

Cat. No.:	HY-12469
CAS No.:	944842-54-0
Molecular Formula:	C ₁₈ H ₁₉ F ₃ N ₆ O
Molecular Weight:	392.38
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (127.43 mM)
* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.5485 mL	12.7427 mL	25.4855 mL
	5 mM	0.5097 mL	2.5485 mL	5.0971 mL
	10 mM	0.2549 mL	1.2743 mL	2.5485 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Decernotinib is a potent, orally active JAK3 inhibitor, with K_is of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

IC₅₀ & Target

JAK3 2.5 nM (K _i)	JAK1 11 nM (K _i)	Tyk2 11 nM (K _i)	JAK2 13 nM (K _i)
FLT3 1 μM (K _i)	ROCK I 1.5 μM (K _i)	GSK3β 1.8 μM (K _i)	CDK2/CycA 2.6 μM (K _i)

	PknB 8 μ M (IC ₅₀)
In Vitro	Decernotinib (VX-509) is a potent JAK3 inhibitor, with K _i s of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively. Decernotinib potently blocks T-cell proliferation with a mean IC ₅₀ of 170 \pm 101 nM, and inhibits IL-2-stimulated T-cell proliferation (IC ₅₀ , 140 and 400 nM). VX-509 is also cytotoxic to B-cell in response to CD40L and IL-4 (IC ₅₀ , 50 nM) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Decernotinib (VX-509, 10, 25, or 50 mg/kg, p.o.) significantly and dose-dependently inhibits the increases in ankle diameter and paw weight occurring in response to collagen injections in rats. Decernotinib potently alleviates cartilage damage and bone resorption in rats. Decernotinib (10, 25, or 50 mg/kg, p.o., b.i.d.) suppresses ear edema in a mouse model of delayed-type hypersensitivity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

The effect of Decernotinib on JAK3 activity is assessed by measuring the residual kinase activity of the recombinantly expressed JAK3 kinase domain using a radiometric assay. The final concentrations of the components in the assay are as follows: 100 mM HEPES (pH 7.5), 10 mM MgCl₂, 1 mM dithiothreitol (DTT), 0.01% BSA, 0.25 nM JAK3, 0.25 mg/mL polyE4Y, and 5 μ M ³³P- γ -ATP (200 μ Ci/ μ mol). A 10 mM stock solution of Decernotinib is prepared in DMSO, from which additional dilutions are prepared. A substrate mixture (100 mM HEPES, 10 mM MgCl₂, 0.5 mg/mL polyE4Y, and 10 μ M ³³P- γ -ATP) is added and mixed with Decernotinib stock solution. The reaction is initiated by the addition of an enzyme mixture [100 mM HEPES (pH 7.5), 10 mM MgCl₂, 2 mM DTT, 0.02% BSA, 0.5 nM JAK3]. After 15 minutes, the reaction is quenched with 20% trichloroacetic acid (TCA). The quenched reaction is transferred to the GF/B filter plates and washed three times with 5% TCA. Following the addition of Ultimate Gold scintillant (50 μ L), the samples are counted in a Packard TopCount gamma counter. In this procedure, the radioactivity trapped is a measure of the residual JAK3 kinase activity. From the activity versus concentration of Decernotinib titration curve, the K_i value is determined by fitting the data to an equation for competitive tight binding inhibition kinetics^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay ^[1]

Whole-blood samples from healthy volunteers are used to collect peripheral blood mononuclear cells, which are plated in T75 tissue culture flasks at a density of 1 \times 10⁶/mL. Cells are stimulated with 10 μ g/mL phytohemagglutinin at 37°C for 72 hours. After 72 hours, cells are detached from the flask by scraping, washed, and plated at a density of 1 \times 10⁵/well in a 96-well plate. Decernotinib (9.7 nM to 10 μ M) is added, and plates are incubated for 30 minutes at 37°C, followed by stimulation with human IL-2. In two rows, only DMSO is added; one row is not stimulated with IL-2, and one row is stimulated with IL-2 to serve as the proliferation control. Plates are incubated at 37°C for 2 days. On day 2, cells are pulsed with 20 μ Ci/mL methyl-[³H]thymidine for 18-24 hours and harvested onto filters for radiographic determination. Data are analyzed to generate an IC₅₀ value using Softmax pro software^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

Rat^[1]

The collagen-induced arthritis (CIA) rat model is used to evaluate the effects of oral Decernotinib [10 mg/kg b.i.d., 25 mg/kg b.i.d., 50 mg/kg b.i.d., 50 mg/kg q.d., or 100 mg/kg q.d.] on joint inflammation and histopathology. Female Lewis rats (157-187 g) are anesthetized with isoflurane and injected with 300 μ L Freund's incomplete adjuvant, containing 2 mg/mL bovine type II collagen, at the base of the tail and two sites on the back on days 0 and 6. The rats are randomized to study groups at the onset of paw swelling (arthritis), which occurs between days 10 and 11. Dosing of either Decernotinib or vehicle via oral gavage is initiated on the first day of established arthritis and continued to day 6 of arthritis. Dosing volume is 5 mL/kg. Groups are controls (no collagen injection plus vehicle; n = 4), collagen plus vehicle (n = 5), collagen plus Decernotinib 10 mg/kg b.i.d. (n = 8); collagen plus Decernotinib 10 mg/kg b.i.d. (n = 8); collagen plus (n = 8); collagen plus (n = 8); collagen plus (n = 8); collagen plu (n = 8); and collagen plus (n = 8); collagen plu (n = 8); all treatments are administered for 6 days. An additional group of rats is given collagen plus 10 mg/kg subcutaneous etanercept, a human tumor necrosis factor- α antagonist, on study days 11 and 14. Caliper measurements of normal (baseline) ankle joints begin on day 9 and continue

through the last day of study. Differences in mean ankle diameter are tested for significance using Student's t test, with significance set at $P \leq 0.05$. The rats are euthanized on day 7 of arthritis, which is study day 17 or 18 depending on when animals are randomized to groups; paws and knees are harvested to determine paw weight and to conduct a histopathological analysis of inflammation (knee and ankle), pannus formation (ankle), cartilage destruction (knee), and bone resorption (knee and ankle). Scores range from 0 (normal) to 5 (severe pathology) and are assigned by a veterinary pathologist. Percent inhibition is calculated using the following formula: $[(\text{mean of treatment group}) - (\text{mean of control})] \div [(\text{mean of collagen + vehicle}) - (\text{mean of control})]$. Kruskal-Wallis one-way analysis of variance nonparametric tests are used to determine statistical significance among the histopathology groups, with significance set at $P \leq 0.05$ ^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Science. 2017 Dec 1;358(6367):eaan4368.
- J Nat Prod. 2021 Mar 16.
- Biochem Biophys Rep. 2020 Oct 15;24:100832.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Mahajan S, et al. VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 Mar 11. pii: jpet.114.221176.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA